| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CLPT.2004.11.112 |
| P698 | PubMed publication ID | 15900284 |
| P50 | author | David J. Greenblatt | Q88911712 |
| Michael H Court | Q91588223 | ||
| Lisa L. von Moltke | Q111458053 | ||
| P2093 | author name string | Ping He | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | midazolam | Q423071 |
| P304 | page(s) | 373-387 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo | |
| P478 | volume | 77 |
| Q37700667 | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State |
| Q38832009 | A Phase 1 Randomized, Placebo-Controlled Study Assessing the Pharmacokinetics, Safety, and Tolerability of Retosiban in Healthy, Nonpregnant Japanese Subjects |
| Q36720920 | Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach |
| Q53077446 | Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. |
| Q37359687 | Association of genotypes of the CYP3A cluster with midazolam disposition in vivo |
| Q28079308 | Balkan endemic nephropathy: an update on its aetiology |
| Q51306296 | CYP gene family variants as potential protective factors in drug addiction in Han Chinese. |
| Q36110529 | CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice |
| Q48098073 | CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin |
| Q47951996 | CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients |
| Q50123785 | Charactering the metabolism of cryptotanshinone by human P450 enzymes and uridine diphosphate glucuronosyltransferases in vitro. |
| Q43954906 | Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients. |
| Q36546247 | Clinical implications of CYP3A polymorphisms |
| Q33977228 | Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. |
| Q38099372 | Cytochrome P450 pharmacogenetics in African populations. |
| Q36960539 | Cytochrome P450 reaction-phenotyping: an industrial perspective |
| Q47096788 | DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer |
| Q42480303 | Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations |
| Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
| Q33640426 | Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs |
| Q83517464 | Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals |
| Q36171561 | Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. |
| Q36558437 | Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania |
| Q34266864 | Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. |
| Q34500741 | Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism |
| Q46581816 | Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients |
| Q28269219 | Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity |
| Q37207247 | Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism |
| Q44029128 | Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease |
| Q45279289 | Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism |
| Q48567513 | Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation |
| Q47292609 | In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. |
| Q28305304 | Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam |
| Q34012749 | Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART |
| Q33451969 | Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system |
| Q34704763 | Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa |
| Q37126092 | Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients |
| Q39752018 | Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. |
| Q34019331 | Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q34562770 | Pharmacogenetics and the concept of individualized medicine |
| Q92354717 | Pharmacogenetics of alcohol addiction: current perspectives |
| Q39198915 | Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl |
| Q45866401 | Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam |
| Q36634077 | Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem |
| Q49381732 | Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers |
| Q80577452 | Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations |
| Q37156272 | Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa |
| Q35183640 | Population pharmacokinetic analysis of sorafenib in patients with solid tumours. |
| Q37369341 | Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans |
| Q38178095 | Race and ethnicity in cancer therapy: what have we learned? |
| Q35089862 | Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus |
| Q37405140 | The impact of pharmacogenetics on HIV therapy |
| Q36729151 | The recovery time-course of CYP3A after induction by St John's wort administration |
| Q36497088 | The role of genetic variability in drug metabolism pathways in breast cancer prognosis |
| Q47411773 | Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity |
| Q37039013 | Update: vildagliptin for the treatment of Type 2 diabetes |
Search more.